Market Research Logo

Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2016

Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H2 2016’, provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Secondary Progressive Multiple Sclerosis (SPMS)
  • The report reviews pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Secondary Progressive Multiple Sclerosis (SPMS) therapeutics and enlists all their major and minor projects
  • The report assesses Secondary Progressive Multiple Sclerosis (SPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS)
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Secondary Progressive Multiple Sclerosis (SPMS) Overview
Therapeutics Development
Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) - Overview
Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics under Development by Companies
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Secondary Progressive Multiple Sclerosis (SPMS) - Products under Development by Companies
Secondary Progressive Multiple Sclerosis (SPMS) - Companies Involved in Therapeutics Development
AB Science SA
Actelion Ltd
Biogen, Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Glialogix, Inc.
Immune Response BioPharma, Inc.
Innate Immunotherapeutics Ltd
Kyorin Pharmaceutical Co., Ltd.
Mallinckrodt Plc
MedDay SA
MedImmune, LLC
Merck KGaA
Meta-IQ ApS
Novartis AG
Opexa Therapeutics, Inc.
Xenetic Biosciences (UK) Limited
Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
7Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
biotin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DC-TAB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etomoxir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLX-1112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GZ-402668 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-MS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibudilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imilecleucel-T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inebilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon beta-1b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IR-902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-2736 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methoxsalen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIS-416 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ocrelizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
opicinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ponesimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
siponimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Xemys - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Secondary Progressive Multiple Sclerosis (SPMS) - Dormant Projects
Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products
Secondary Progressive Multiple Sclerosis (SPMS) - Product Development Milestones
Featured News & Press Releases
May 25, 2016: MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial
Apr 21, 2016: MedDay reports full data from pivotal Phase IIb/III MS-SPI / MS-ON studies with MD1003 in Multiple Sclerosis at AAN
Apr 13, 2016: Innate Immunotherapeutics announces clinical trial fully enrolled and receives strong interest from potential Pharma partners
Apr 01, 2016: PJSC Pharmsynthez Completes Follow Up and Data Analysis From a Phase 2 Study of Novel Therapeutic Vaccine Xemys for Multiple Sclerosis
Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis
Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003
Oct 07, 2015: MedDay reports additional positive analyses of its pivotal study with MD1003 in patients with primary and secondary Progressive Multiple Sclerosis
Oct 06, 2015: Opexa Announces Granting of New T-cell Patents Covering Tcelna; Patent Estate Increases to 160 Issued Patents
Aug 06, 2015: Medical Need Europe appoints Durbin as latest distribution partner
Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting
Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC
Oct 07, 2014: Update on Innate’s Phase 2B trial and other recent activities
Aug 19, 2014: Innate’s Phase 2B clinical trial on SPMS to start recruiting patients following Perth site obtaining ethics approval
Jun 20, 2014: Update on Phase 2B Trial of MIS416 in Patients with Secondary Progressive Multiple Sclerosis
Jun 18, 2014: Compassionate Use Programme Update
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by AB Science SA, H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Actelion Ltd, H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Biogen, Inc., H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Genzyme Corporation, H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Glialogix, Inc., H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Immune Response BioPharma, Inc., H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Innate Immunotherapeutics Ltd, H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Mallinckrodt Plc, H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by MedDay SA, H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by MedImmune, LLC, H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Merck KGaA, H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Meta-IQ ApS, H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Novartis AG, H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Opexa Therapeutics, Inc., H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Dormant Projects, H2 2016
Secondary Progressive Multiple Sclerosis (SPMS) - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report